"The retraction of a 2011 paper claiming amyloid-β was responsible for memory loss in Alzheimer's disease is part of a troubling trend, with multiple studies being retracted over the years. This raises serious questions about the validity of the amyloid hypothesis, which has dominated Alzheimer's research for decades."
"Despite the focus on amyloid-β, none of the drugs targeting this protein have demonstrated any real clinical effect, leading to skepticism about the direction of Alzheimer's research and the efficacy of current treatment strategies."
The retraction of a 2011 paper on amyloid-β's role in Alzheimer's disease reflects a broader trend of multiple studies being withdrawn. Despite decades of research, drugs targeting amyloid-β have shown no significant clinical effects. Alzheimer's disease, first identified in 1906, was linked to plaques and tangles in the brain, with amyloid-β identified in 1984. Advances in diagnostic techniques have occurred, yet the understanding of amyloid-β's function remains unclear, raising questions about the validity of long-held theories in Alzheimer's research.
Read at Ars Technica
Unable to calculate read time
Collection
[
|
...
]